Back to Search Start Over

Formulation of three tailed bacteriophages by spray-drying and atomic layer deposition for thermal stability and controlled release.

Authors :
Coleman HJ
Yang Q
Robert A
Padgette H
Funke HH
Catalano CE
Randolph TW
Source :
Journal of pharmaceutical sciences [J Pharm Sci] 2024 Nov; Vol. 113 (11), pp. 3238-3245. Date of Electronic Publication: 2024 Aug 22.
Publication Year :
2024

Abstract

Deep infection is the second most common complication of arthroplasty following loosening of the implant. Antibiotic-loaded bone cements (ALBCs) and high concentrations of systemic broad-spectrum antibiotics are commonly used to prevent infections following injury and surgery. However, clinical data fails to show that ALBCs are effective against deep infection, and negative side effects can result following prolonged administration of antibiotics. Additionally, the rise of multidrug resistant (MDR) bacteria provides an urgent need for alternatives to broad-spectrum antibiotics. Phage therapy, or the use of bacteriophages (viruses that infect bacteria) to target pathogenic bacteria, might offer a safe alternative to combat MDR bacteria. Application of phage therapy in the setting of deep infections requires formulation strategies that would stabilize bacteriophage against chemical and thermal stress during bone-cement polymerization, that maintain bacteriophage activity for weeks or months at physiological temperatures, and that allow for sustained release of phage to combat slow-growing, persistent bacteria. Here, we demonstrate the formulation of three phages that target diverse bacterial pathogens, which includes spray-drying of the particles for enhanced thermal stability at 37 °C and above. Additionally, we use atomic layer deposition (ALD) to coat spray-dried powders with alumina to allow for delayed release of phage from the dry formulations, and potentially protect phage against chemical damage during bone cement polymerization. Together, these findings present a strategy to formulate phages that possess thermal stability and sustained release properties for use in deep infections.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The University of Colorado has licensed intellectual property related to thermal stabilization and ALD coatings of vaccines to VitriVax, Inc., a company in which the Regents of the University of Colorado and TWR hold equity.<br /> (Copyright © 2024 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1520-6017
Volume :
113
Issue :
11
Database :
MEDLINE
Journal :
Journal of pharmaceutical sciences
Publication Type :
Academic Journal
Accession number :
39173744
Full Text :
https://doi.org/10.1016/j.xphs.2024.08.005